Debbie Feinstein: FTC limited in ability to tackle drug price hikes

The director of the Federal Trade Commission’s bureau of competition yesterday said the agency’s ability to address high drug prices depends on whether a company has committed an antitrust violation.

Unlock unlimited access to all Global Competition Review content